Nektar Therapeutics (NASDAQ:NKTR) Director Lutz Lingnau sold 10,000 shares of the firm’s stock in a transaction dated Monday, July 8th. The stock was sold at an average price of $34.63, for a total transaction of $346,300.00. Following the transaction, the director now directly owns 33,200 shares in the company, valued at $1,149,716. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Shares of Nektar Therapeutics stock opened at $33.53 on Friday. The company has a market cap of $6.08 billion, a price-to-earnings ratio of 8.87 and a beta of 2.75. The company has a quick ratio of 14.83, a current ratio of 14.94 and a debt-to-equity ratio of 0.21. The firm’s 50 day moving average is $34.01. Nektar Therapeutics has a 1 year low of $29.22 and a 1 year high of $69.76.

Nektar Therapeutics (NASDAQ:NKTR) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $0.03. The company had revenue of $28.22 million for the quarter, compared to analyst estimates of $25.45 million. Nektar Therapeutics had a net margin of 55.65% and a return on equity of 37.63%. During the same period in the previous year, the firm posted ($0.60) EPS. As a group, equities research analysts predict that Nektar Therapeutics will post -3.14 EPS for the current year.

Several institutional investors have recently made changes to their positions in NKTR. Meeder Asset Management Inc. grew its holdings in shares of Nektar Therapeutics by 150.2% during the 1st quarter. Meeder Asset Management Inc. now owns 798 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 479 shares during the last quarter. Quantamental Technologies LLC acquired a new stake in Nektar Therapeutics during the 1st quarter worth approximately $27,000. CSat Investment Advisory L.P. boosted its position in Nektar Therapeutics by 279.2% during the 4th quarter. CSat Investment Advisory L.P. now owns 1,073 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 790 shares during the period. Enterprise Financial Services Corp acquired a new stake in Nektar Therapeutics during the 1st quarter worth approximately $67,000. Finally, Belpointe Asset Management LLC acquired a new stake in Nektar Therapeutics during the 1st quarter worth approximately $100,000. 92.23% of the stock is currently owned by institutional investors.

A number of equities analysts recently commented on the stock. Mizuho reaffirmed a “buy” rating and set a $81.00 price target on shares of Nektar Therapeutics in a research report on Friday, May 24th. Svb Leerink began coverage on shares of Nektar Therapeutics in a report on Friday, March 15th. They issued a “mkt perform” rating and a $38.00 target price on the stock. William Blair reissued a “buy” rating on shares of Nektar Therapeutics in a report on Friday, June 14th. ValuEngine lowered shares of Intersect ENT from a “buy” rating to a “hold” rating in a report on Monday, June 3rd. Finally, BidaskClub raised shares of Zynerba Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Thursday, June 20th. One analyst has rated the stock with a sell rating, three have given a hold rating and nine have issued a buy rating to the company’s stock. Nektar Therapeutics has an average rating of “Buy” and an average price target of $68.50.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company develops NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; and NKTR-214, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in Phase I to treat immuno-oncology.

See Also: Cash Flow

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.